PV Bulletin

EMA/HMA Workshop Recommendations on Mechanistic Model Reporting and Qualification

HMA/EMA workshop report recommends establishing a standing forum for strategic MIDD dialogue, enhancing product-specific interaction pathways, and updating guidance on qualification and reporting of mechanistic models (e.g., QSP/QST) for regulatory assessment.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

Urgency: LowConfidence: high

What changed

EMA and HMA issued final workshop recommendations establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific MIDD pathways, and updating guidance to delineate platform qualification and reporting requirements for mechanistic models.

Why it matters

Mechanistic models are increasingly used in safety assessment and signal management; these recommendations will directly affect how sponsors prepare and present mechanistic safety evidence in dossiers and safety reviews within the EU.

Action needed

Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

monitor

Policy change details

Document type
Report
Policy status
final
Publication date
2026-06-05
Policy change
This report summarizes the findings of a workshop focused on the reporting and qualification of mechanistic models (e.g., QSP/QST) within the EU regulatory framework. It outlines recommendations for strategic dialogue and guidance refinement to streamline the use of these models in regulatory assessment.

Key changes

Key recommendations include establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific interaction pathways for MIDD, and updating guidance to delineate platform qualification and reporting requirements.

Affected workflows

Signal Management

Responsible groups

Pharmacovigilance OperationsRegulatory AffairsSafety/Pharmacology Teams

PV impact

Mechanistic models are increasingly used in safety assessment and signal management. The recommendations for clearer qualification pathways and reporting requirements will impact how sponsors present mechanistic safety evidence in dossiers and safety reviews.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

The report outlines recommendations to streamline the use of mechanistic models in EU regulatory assessment, including clearer qualification pathways and reporting requirements, impacting how sponsors present mechanistic safety evidence.

What changed: EMA and HMA issued final workshop recommendations establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific MIDD pathways, and updating guidance to delineate platform qualification and reporting requirements for mechanistic models.

Why it matters: Mechanistic models are increasingly used in safety assessment and signal management; these recommendations will directly affect how sponsors prepare and present mechanistic safety evidence in dossiers and safety reviews within the EU.

Practical implication: Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward